Nano Cap New Millennium Growth Fund L P Acquires New Position in GoodRx Holdings, Inc. $GDRX

Nano Cap New Millennium Growth Fund L P acquired a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the fourth quarter, according to its most recent 13F filing with the SEC. The fund acquired 585,000 shares of the company’s stock, valued at approximately $1,585,000. GoodRx accounts for 1.4% of Nano Cap New Millennium Growth Fund L P’s portfolio, making the stock its 17th largest holding. Nano Cap New Millennium Growth Fund L P owned 0.17% of GoodRx as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. LSV Asset Management lifted its position in shares of GoodRx by 517.1% during the third quarter. LSV Asset Management now owns 2,354,581 shares of the company’s stock worth $9,960,000 after acquiring an additional 1,973,017 shares in the last quarter. Universal Beteiligungs und Servicegesellschaft mbH purchased a new stake in shares of GoodRx during the third quarter worth $3,036,000. Pathway Capital Management LP boosted its position in shares of GoodRx by 69.0% in the third quarter. Pathway Capital Management LP now owns 986,158 shares of the company’s stock valued at $4,171,000 after acquiring an additional 402,721 shares during the period. Prescott Group Capital Management L.L.C. bought a new position in shares of GoodRx in the fourth quarter valued at approximately $4,812,000. Finally, CWM LLC boosted its position in shares of GoodRx by 299.7% in the fourth quarter. CWM LLC now owns 23,305 shares of the company’s stock valued at $63,000 after acquiring an additional 17,474 shares during the period. Hedge funds and other institutional investors own 63.77% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Mizuho cut their price objective on shares of GoodRx from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Friday, February 27th. TD Cowen raised their price objective on shares of GoodRx from $3.00 to $4.00 and gave the company a “buy” rating in a research report on Monday, May 11th. The Goldman Sachs Group restated a “neutral” rating and issued a $3.50 price objective on shares of GoodRx in a research report on Friday, May 8th. Weiss Ratings cut GoodRx from a “sell (d+)” rating to a “sell (d)” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. restated a “neutral” rating on shares of GoodRx in a research report on Friday, February 27th. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $3.81.

GoodRx Price Performance

Shares of NASDAQ:GDRX opened at $2.56 on Friday. The company’s fifty day moving average price is $2.29 and its 200-day moving average price is $2.51. The firm has a market capitalization of $876.98 million, a price-to-earnings ratio of 42.67, a PEG ratio of 1.61 and a beta of 1.54. GoodRx Holdings, Inc. has a one year low of $1.77 and a one year high of $5.81. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.47 and a quick ratio of 1.47.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.07 EPS for the quarter, hitting analysts’ consensus estimates of $0.07. The firm had revenue of $194.01 million for the quarter, compared to analyst estimates of $185.40 million. GoodRx had a net margin of 2.61% and a return on equity of 7.90%. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.09 EPS. On average, equities research analysts anticipate that GoodRx Holdings, Inc. will post 0.17 earnings per share for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.